glp 1 agonist comparison Comparing GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual (#tirzepatide) have been FDA-approved for #weightloss in adults comparison of glp 1 agonists
Description
Changes in regional body composition over 8 years in a randomized lifestyle trial: The look AHEAD study
One study reports Ozempic can cause weight loss of 4% to 6.2% body mass in diabetics , with an even more impressive effect size of 6.1% to 17.4% in non-diabetics
Budhiraja P, Reddy KS, Butterfield RJ, Jadlowiec CC, Moss AA, Khamash HA, Kodali L, Misra SS, Heilman RL
Competing interests J.O
These reductions were observed across different BMI ranges, making the pill a potential option for a broad set of adults with obesity
